

IN THE CLAIMS:

1. (Currently Amended) A method for modulating migration of a cell that expresses a galectin-3 receptor, said cell capable of having migration modulated by galectin-3, comprising contacting the cell with a migration-~~modulating~~ increasing or migration-decreasing amount of galectin-3.
2. (Currently Amended) A method for modulating monocyte, neutrophil, eosinophil, or macrophage migration comprising contacting a monocyte, neutrophil, eosinophil, or macrophage with a migration-~~modulating~~ increasing or migration-decreasing amount of galectin-3.
3. (Original) The method of claim 1 or 2, wherein the migration is stimulated.
4. (Original) The method of claim 1 or 2, wherein the migration is inhibited.
5. (Previously Presented) The method of claim 1 or 2, wherein the method uses a subsequence of galectin-3.
6. (Currently Amended) The method of claim 1 or 2, wherein the galectin-3 comprises a fragment thereof of galectin-3.
7. (Original) The method of claim 1 or 2, wherein the migration is modulated in an animal.
8. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-increasing amount of galectin-3.
9. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of galectin-3.
10. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to a tumor comprising contacting the tumor with a migration-increasing amount of galectin-3.
11. (Previously Presented) A method for decreasing migration of monocytes, neutrophils, eosinophils, or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-decreasing amount of galectin-3.
12. (Previously Presented) A method for decreasing migration of monocytes, neutrophils, eosinophils, or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of galectin-3.

13. (Canceled)
14. (Withdrawn) A method for identifying an agent that modulates galectin-3 mediated cell migration comprising:
contacting galectin-3 with a test agent; and
detecting galectin-3 mediated cell migration,
wherein an alteration of galectin-3 mediated cell migration in the presence of the test agent identifies an agent that modulates galectin-3 mediated cell migration.
15. (Withdrawn) The method of claim 14, wherein the agent increases galectin-3 mediated migration.
16. (Withdrawn) The method of claim 14, wherein the agent decreases galectin-3 mediated migration.
17. (Withdrawn) The method of claim 14, wherein the agent is a small molecule.
18. (Withdrawn) The method of claim 14, wherein the contacting is *in vitro*, intracellular, or *in vivo*.
19. (Withdrawn) A composition comprising an agent identified according to the method of claim 14.
20. (Withdrawn) The composition of claim 19, wherein the agent is a saccharide.
21. (Withdrawn) The composition of claim 20, wherein the saccharide is lactose, galactose, beta-galactoside, or an analog or derivative thereof.
22. (Withdrawn) The composition of claim 19, wherein the composition further comprises a drug.
23. (Withdrawn) A composition comprising a migration-modulating amount of an antibody that specifically binds galectin-3 and a suitable carrier, excipient or diluent.
24. (Withdrawn) A composition comprising a migration-modulating amount of an antibody that specifically binds galectin-3 and a drug.
25. (Withdrawn) A composition comprising a migration-modulating amount of galectin-3 or a functional subsequence thereof and a pharmaceutically acceptable carrier, excipient or diluent.
26. (Withdrawn) The composition of claim 25, wherein the composition further comprises a drug.

27. (Withdrawn) The composition of claim 22, or 24, or 26, wherein the drug is an anti-tumor, antiviral, antibacterial, anti-mycobacterial, anti-fungal, anti-cell proliferative or apoptotic agent.
28. (Withdrawn) A composition comprising galectin-3 or a functional subsequence thereof and an article of manufacture.
29. (Withdrawn) The composition of claim 28, wherein the article of manufacture comprises a dressing.
30. (Withdrawn) The composition of claim 29, wherein the dressing comprises a bandage, a suture, a sponge, or a surgical dressing.
31. (Withdrawn) A microfabricated device containing galectin-3 or a functional subsequence thereof in a pharmaceutically acceptable carrier, said device capable of controlled delivery of the galectin-3 or the functional subsequence.
32. (Withdrawn) The device of claim 31, wherein the device can be implanted in the body of a subject.
33. (Withdrawn) The device of claim 32, wherein the implantation site is a site of infection.
34. (Withdrawn) The device of claim 32, wherein the implantation site is in close proximity to or within a solid tumor.
35. (Withdrawn) The device of claim 32, wherein the implantation site is a site of a lesion.
36. (Currently Amended) A method for modulating migration of a cell that expresses a galectin-3 receptor comprising contacting the cell with a migration-~~modulating~~ increasing or migration-decreasing amount of a galectin-3 binding antibody.
37. (Currently Amended) A method for modulating monocyte, neutrophil, eosinophil, or macrophage migration comprising contacting a monocyte, neutrophil, eosinophil, or macrophage with a migration-~~modulating~~ increasing or migration-decreasing amount of a galectin-3 binding antibody.
38. (Previously Presented) The method of claim 36 or 37, wherein the migration is stimulated.
39. (Previously Presented) The method of claim 36 or 37, wherein the migration is inhibited.
40. (Previously Presented) The method of claim 36 or 37, wherein the method uses a subsequence of galectin-3.

41. (Currently Amended) The method of claim 36 or 37, wherein the galectin-3 binding antibody comprises a binding fragment ~~thereof~~ of galectin-3 binding antibody.
42. (Previously Presented) The method of claim 36 or 37, wherein the migration is modulated in an animal.
43. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-increasing amount of a galectin-3 binding antibody.
44. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of a galectin-3 binding antibody.
45. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to a tumor comprising contacting the tumor with a migration-increasing amount of a galectin-3 binding antibody.
46. (Previously Presented) A method for decreasing migration of monocytes, neutrophils, eosinophils, or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-decreasing amount of a galectin-3 binding antibody.
47. (Previously Presented) A method for increasing migration of monocytes, neutrophils, eosinophils, or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of a galectin-3 binding antibody.